Celularity (NASDAQ:CELU – Get Free Report) and Upstream Bio (NASDAQ:UPB – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, institutional ownership, profitability, analyst recommendations and valuation.
Insider and Institutional Ownership
19.0% of Celularity shares are held by institutional investors. 17.3% of Celularity shares are held by insiders. Comparatively, 16.5% of Upstream Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Celularity and Upstream Bio”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Celularity | $26.55 million | 1.00 | -$91.72 million | ($1.69) | -0.48 |
| Upstream Bio | $2.85 million | 65.15 | -$143.44 million | ($2.90) | -1.17 |
Celularity has higher revenue and earnings than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Celularity and Upstream Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Celularity | -246.65% | N/A | -48.20% |
| Upstream Bio | -4,955.67% | -48.40% | -46.57% |
Volatility and Risk
Celularity has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Upstream Bio has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and price targets for Celularity and Upstream Bio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Celularity | 1 | 0 | 0 | 0 | 1.00 |
| Upstream Bio | 1 | 2 | 4 | 0 | 2.43 |
Upstream Bio has a consensus target price of $29.67, suggesting a potential upside of 775.12%. Given Upstream Bio’s stronger consensus rating and higher possible upside, analysts plainly believe Upstream Bio is more favorable than Celularity.
Summary
Celularity beats Upstream Bio on 7 of the 13 factors compared between the two stocks.
About Celularity
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.
About Upstream Bio
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.
